Get the Stockscreener App
60.04
0.45%
-0.27
Pre-market:
60.39
0.35
+0.58%
Cytokinetics Inc stock is traded at $60.04, with a volume of 1.31M.
It is down -0.45% in the last 24 hours and up +15.46% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$60.31
Open:
$60.27
24h Volume:
1.31M
Relative Volume:
0.62
Market Cap:
$7.18B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-11.41
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
+5.39%
1M Performance:
+15.46%
6M Performance:
+58.63%
1Y Performance:
+12.96%
1-Day Range:
$58.58
$60.50
1-Week Range:
$57.27
$61.48
52-Week Range:
$29.31
$61.48
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
60.04 | 7.22B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Aberdeen Group plc Buys 320,508 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Securities Lawsuit Alert: Cytokinetics, Incorporated (CYTK)Contact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - FinancialContent
Cytokinetics, Incorporated $CYTK Stake Increased by Mirae Asset Global Investments Co. Ltd. - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits - GlobeNewswire Inc.
Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class ActionCYTK - PR Newswire
State of Alaska Department of Revenue Decreases Stake in Cytokinetics, Incorporated $CYTK - Defense World
Weiss Ratings Reiterates "Sell (D-)" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PR Newswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCYTK - Eastern Progress
Portnoy Law Firm Announces Class Action on Behalf of Cytokinetics, Incorporated. Investors - GlobeNewswire
Deadline Alert: Cytokinetics, Incorporated (CYTK) - GlobeNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - GuruFocus
How Cytokinetics Incorporated stock benefits from tech adoptionTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Top chart patterns to watch in Cytokinetics IncorporatedWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
Should I hold or sell Cytokinetics Incorporated stock in 2025July 2025 Summary & Low Drawdown Trading Strategies - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo
Cytokinetics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment landscape - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming DeadlinesCYTK - PR Newswire
Cytokinetics, Inc. Hits New 52-Week High at $61.00 - Markets Mojo
Cytokinetics Shareholder Alert By Former Louisiana Attorney - GlobeNewswire
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 2,000 Shares - MarketBeat
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cytokinetics, - GlobeNewswire
Malik, Cytokinetics evp, sells $121k in shares - Investing.com
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of VFC, - GlobeNewswire
December 19th Options Now Available For Cytokinetics (CYTK) - Nasdaq
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - PR Newswire
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming - GuruFocus
Robbins LLP Reminds Cytokinetics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against CYTK - PR Newswire
Insider Sell: Kaye Edward M. MD Sells 6,757 Shares of Cytokineti - GuruFocus
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
Investors in Cytokinetics, Incorporated (CYTK): Protect Your RightsContact Levi & Korsinsky Before November 17, 2025 - ACCESS Newswire
CYTK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Cytokinetics, Incorporated Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit | FinancialContent - FinancialContent
Cytokinetics stock hits 52-week high at 59.5 USD - Investing.com
Cytokinetics stock hits 52-week high at 59.5 USD By Investing.com - Investing.com Australia
Barclays Raises Price Target for Cytokinetics (CYTK) to $82 | CY - GuruFocus
Class Action Filed Against Cytokinetics, Incorporated (CYTK)November 17, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar
Lost Money on Cytokinetics, Incorporated (CYTK)? Contact Levi & Korsinsky Before November 17, 2025 to Join Class Action - ACCESS Newswire
Lost Money on Cytokinetics, Incorporated (CYTK)? Join Class Action Before November 17, 2025Contact Levi & Korsinsky - ACCESS Newswire
Can Cytokinetics Incorporated (KK3A) stock sustain breakout momentumEarnings Recap Report & Real-Time Volume Triggers - newser.com
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit - Eastern Progress
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel ... - Caledonian Record
J. Safra Sarasin Holding AG Grows Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, IncorporatedCYTK - MarketScreener
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Oct 07 '25 |
Sale |
60.56 |
2,000 |
121,120 |
140,610 |
| Kaye Edward M. MD | Director |
Oct 06 '25 |
Sale |
60.00 |
6,757 |
405,420 |
9,778 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):